British American Tobacco (BATS) H1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
H1 2026 earnings summary
6 Aug, 2026Executive summary
H1 2026 results met expectations, with revenue up 2.9% at constant FX and adjusted profit from operations up 3.5%, driven by strong U.S. multi-category performance and robust New Category momentum.
Smokeless products now account for 19.8% of group revenue, with 4.1 million new smokeless consumers added, totaling 35 million.
New Category contribution rose 55% to £269m, with Modern Oral up 65.9% and U.S. Vapour returning to double-digit growth.
Resilient combustibles performance, especially in the U.S. and AME, supported by cost-saving initiatives.
Transformation momentum is supported by disciplined investment, targeted resource allocation, and ongoing cost optimization.
Financial highlights
Group revenue: £12,235m (+1.4% reported, +2.9% constant FX); New Category revenue grew 18% to £1,928m.
Adjusted profit from operations: £5,421m (+3.5% constant FX, as adjusted for Canada); adjusted diluted EPS up 7.9% to 164.0p.
Adjusted gross profit increased 3.8% to £8.3bn; adjusted operating margin at 43.7% (+30bps, as adjusted for Canada).
Free cash flow generation remains strong, targeting over £50bn from 2024-2030; cash conversion above 95% expected for the full year.
Share buy-back programme on track for £1.3bn in 2026; leverage target of 2.0-2.5x by year-end.
Outlook and guidance
FY26 guidance reaffirmed: 3-5% revenue growth, mid-teens New Category revenue growth, 4-6% adjusted profit from operations growth (H2 weighted).
Adjusted diluted EPS growth expected toward the middle of 5-8% guidance range.
Operating cash flow conversion expected to exceed 95%; leverage to be within 2.0-2.5x corridor.
Net finance cost for the year expected around £1.65bn; underlying tax rate 24%-25%.
Commitment to progressive dividend and £1.3bn share buy-back for FY26; gross capital expenditure for 2026 expected at ~£750m.
Latest events from British American Tobacco
- New category growth and cost discipline offset regulatory and illicit trade headwinds in 2024.BATS
H2 202420 Jul 2026 - H1 revenue up 1.8% at constant FX, led by Modern Oral and U.S. growth; profit up 19.1%.BATS
H1 20258 Jul 2026 - Mid-teens revenue growth led by Modern Oral and Vapour, with robust U.S. and cash generation momentum.BATS
Trading update2 Jun 2026 - FY25 delivered top-end results, led by Modern Oral and New Category growth, strong U.S. and AME performance.BATS
H2 202513 Apr 2026 - Accelerating smokeless transformation and U.S. growth through innovation and regulatory action.BATS
Consumer Analyst Group of New York Conference (CAGNY) 202619 Feb 2026 - New Category growth and innovation offset U.S. headwinds, supporting full-year guidance.BATS
H1 20243 Feb 2026 - Guidance reaffirmed as new categories and innovation drive H2 acceleration and cash returns.BATS
Trading Update31 Jan 2026 - Accelerating innovation and smokeless growth, with robust financials and U.S. market stabilization.BATS
21st Annual dbAccess Global Consumer Conference 202431 Jan 2026 - Accelerates smokeless transformation, targeting >50% revenue from new categories by 2035.BATS
CMD 202419 Jan 2026